NAV
$29.09
AUM
$7.8M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ASML.AS | ASML Holding NV | 5.68% |
| 2 | ROP.SW | Roche Holding AG Ordinary Shares new | 3.48% |
| 3 | BHP.AX | BHP Group Ltd | 2.96% |
| 4 | DTE.DE | Deutsche Telekom AG | 2.26% |
| 5 | NOVN.SW | Novartis AG Registered Shares | 2.25% |
| 6 | NOVO-B.CO | Novo Nordisk AS Class B | 2.07% |
| 7 | INVE B | Investor AB Class B | 2.06% |
| 8 | AZN.L | AstraZeneca PLC | 1.94% |
| 9 | BATS.L | British American Tobacco PLC | 1.89% |
| 10 | ALV.DE | Allianz SE | 1.69% |
Under normal circumstances, the fund will invest at least 80% of its net assets in equity securities of large-capitalization companies located in developed markets outside of North America, which generally include markets such as Australia, Austria, Belgium, Denmark, Finland, France, Germany, Hong Kong, Ireland, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Norway, Singapore, Spain, Sweden, Switzerland, and the United Kingdom. The fund is non-diversified.
Inception Date: 2025-12-10